Sigilon Therapeutics Company

Sigilon is a biotech company which specializes in creating immune privileged products for unmet clinical needs.
Technology: Cell-based gene therapy, Stem cell therapy
Industry: P4 Medicine, Public
Headquarters: Cambridge, Massachusetts, United States
Founded Date: 2015-01-01
Employees Number: 51-100
Funding Status: IPO
Investors Number: 5
Total Funding: 263200000
Estimated Revenue: $10M to $50M
Last Funding Date: 2020-12-03
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership